



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



PRODUCT INFORMATION



TCN 201

Item No. 19086

CAS Registry No.: 852918-02-6

Formal Name: 4-[[[(3-chloro-4-fluorophenyl)sulfonyl]amino]methyl]-benzoic acid 2-benzoylhydrazide

MF: C₂₁H₁₇ClFN₃O₄S

FW: 461.9


Purity: ≥95%

UV/Vis.: λ_{max}: 232 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly



Laboratory Procedures

TCN 201 is supplied as a crystalline solid. A stock solution may be made by dissolving the TCN 201 in the solvent of choice. TCN 201 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of TCN 201 in these solvents is approximately 20 and 15 mg/ml, respectively.

TCN 201 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, TCN 201 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. TCN 201 has a solubility of approximately 0.02 mg/ml in a 1:40 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

TCN 201 is a selective antagonist of NMDA receptors containing the NR2A subunit (pIC₅₀s = 6.8 and <4.3 for human recombinant NR2A and NR2B, respectively).¹ It has been shown to bind to a novel allosteric site located at the dimer interface between the GluN1 and GluN2 binding domains, thereby reducing glycine signal transduction and inhibiting NMDA receptor function.²

References

1. Bettini, E., Sava, A., Griffante, C., *et al.* Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors. *J. Pharmacol. Exp. Ther.* **335**(3), 636-644 (2010).
2. Hansen, K.B., Ogden, K.K., and Traynelis, S.F. Subunit-selective allosteric inhibition of glycine binding to NMDA receptors. *J. Neurosci.* **32**(18), 6197-6208 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/13/2016

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM